Macrogenics (MGNX) risk factors
Item 1A of every Macrogenics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors45 risks6 new4 dropped12 reworded
MacroGenics faces a partial clinical hold on the LINNET study after Grade 5 and other severe adverse events. The company relies on third parties for companion diagnostics and CDMO services at its Rockville facility. Employee headcount dropped from 341 to 293 full-time workers.
Filed Mar 09, 2026 - FY2024 10-K risk factors43 risks
MacroGenics faces significant ongoing financial losses with an accumulated deficit of approximately $1.2 billion and a critical need for substantial additional funding. The company relies heavily on clinical trials for multiple product candidates and key development and commercialization collaborations. Operations are subject to extensive regulatory oversight, intellectual property challenges, and strict healthcare laws.
Filed Mar 20, 2025